Matches 1 - 32 out of 32
Match Document Document Title
7351855 Chemically defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
EP1808183A2 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
7208156 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule  
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
7163683 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule  
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
7138244 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule  
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
7115581 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
7115383 Assays for amphetamine and methamphetamine  
Methods, compositions and kits are disclosed. The compounds disclosed comprise an amphetamine moiety and a methamphetamine moiety linked together by a first linking group. A second linking group...
7083959 Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry  
The present invention relates to a method of specifically suppressing an undesired immune response in a mammal suffering from such a response. The method comprises: i) preparing a construct...
7037669 Assays for amphetamine and methamphetamine using stereospecific reagents  
Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and/or a methamphetamine. Immunogenic conjugates of...
7022492 Ecstasy haptens and immunogens  
Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I are employed in assays for the determination of an methylenedioxyamphetamine, a methylene-dioxyethamphetamine, and/or a...
6991911 Assay for entactogens  
Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxyamphetamine (MDA),...
6951939 Multivalent platform molecules comprising high molecular weight polyethylene oxide  
Valency platform molecules comprising high molecular weight polyethylene oxide groups are provided, as well as conjugates thereof with biologically active molecules, and methods for their...
6375951 Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry  
The invention features a non-immunogenic construct for reducing a non-primary antibody response to an epitope of a T-dependent antigen. The construct is free of high molecular weight...
6340460 Therapeutic suppression of specific immune response by administration of oligomeric forms of antigen of controlled chemistry  
A method of making a non-immunogenic construct for reducing a non-primary antibody response to an epitope of a T-dependent antigen by coupling two or more copies of the epitope to a nonimmunogenic...
6060056 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule  
Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when...
6022544 Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry  
The invention features a method for reducing an undesired antibody response in a mammal by administering to the mammal a non-immunogenic construct which is free of high molecular weight...
5874552 Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides  
Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R 1 and R 2 are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to...
5786512 Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides  
Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R 1 and R 2 are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to...
5774969 Modular model vehicle assembly  
A modular vehicle includes a plurality of modular members arranged on a base. The modular members collectively approximate the contour of a vehicle interior or exterior. The modular members are...
5726329 Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides  
Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R 1 and R 2 are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to...
5633395 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
5606047 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
5578320 Method of dehydrating liposomes using protective sugars  
Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably,...
5552391 Chemically-defined non-polymeric valency platform molecules and conjugates thereof  
Chemically-defined, non-polymeric valency platform molecules and conjugates comprising chemically-defined valency platform molecules and biological or chemical molecules including polynucleotide...
5391785 Intermediates for providing functional groups on the 5' end of oligonucleotides  
Phosphoramidites of the formula ##STR1## where R is a base-labile protecting group, R 1 and R 2 are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to...
5370871 Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry  
The present invention relates to a vaccine derived from a bacterial or virus product that initially comprises a mixture of polymers of varying molecular weights. The vaccine contains an...
5276013 Conjugates of biologically stable polyfunctional molecules and polynucleotides for treating systemic lupus erythematosus  
Chemically defined conjugates of biologically stable valency platform molecules, such as copolymers of D-glutamic acid and D-lysine or polyethylene glycol, and polynucleotide duplexes of at least...
5162515 Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus  
Chemically defined conjugates of biologically stable polymers, such as copolymers of D-glutamic acid and D-lysine, and polynucleotide duplexes of at least 30 base pairs that have significant...
5134071 Polymerization and copolymerization of proteins  
A method for producing a polyprotein having at least 10 units, and often as many as 50 to 100 and more units held together by sulfur to sulfur or sulfur to carbon bonds is disclosed. Each unit...
4990336 Sustained release dosage form  
A multiphasic sustained release injectable delivery system is provided, as well as a method for treating humans and other mammals with that multiphasic sustained release system. The multiphasic...
4952519 Protein immobilization with poly(ethyleneimine) derivatized with a hydroprobic group  
A member of a bioaffinity binding pair is immobilized on a plastic surface by coating the surface with poly(ethyleneimine) derivatized with a hydrophobic group, and covalently coupling the member...
4582810 Immuno-agglutination particle suspensions  
A suspension of diagnostic particles comprising antibody molecules attached to a carboxylate derivatized polymer core is provided for agglutination tests. The antibody is linked to the core through...
Matches 1 - 32 out of 32